Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms
Genes · 06.11.2023 · 14 (11) · 2048
DOI: 10.3390/genes14112048 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 06.11.2023. Verfasst von Barbara Vuic und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, Croatia. Hauptthemen laut MEDLINE: Pharmacogenetics, Alzheimer Disease. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 314 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Croatian Science Foundation.
Themen: Demenz
Abstract (Originalsprache)
Dementia is a syndrome of global and progressive deterioration of cognitive skills, especially memory, learning, abstract thinking, and orientation, usually affecting the elderly. The most common forms are Alzheimer’s disease, vascular dementia, and other (frontotemporal, Lewy body disease) dementias. The etiology of these multifactorial disorders involves complex interactions of various environmental and (epi)genetic factors and requires multiple forms of pharmacological intervention, including anti-dementia drugs for cognitive impairment, antidepressants, antipsychotics, anxiolytics and sedatives for behavioral and psychological symptoms of dementia, and other drugs for comorbid disorders. The pharmacotherapy of dementia patients has been characterized by a significant interindividual variability in drug response and the development of adverse drug effects. The therapeutic response to currently available drugs is partially effective in only some individuals, with side effects, drug interactions, intolerance, and non-compliance occurring in the majority of dementia patients. Therefore, understanding the genetic basis of a patient’s response to pharmacotherapy might help clinicians select the most effective treatment for dementia while minimizing the likelihood of adverse reactions and drug interactions. Recent advances in pharmacogenomics may contribute to the individualization and optimization of dementia pharmacotherapy by increasing its efficacy and safety via a prediction of clinical outcomes. Thus, it can significantly improve the quality of life in dementia patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, Croatia.
- Department for Biological Psychiatry and Psychogeriatry, University Hospital Vrapce, 10000 Zagreb, Croatia.
- School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
ORCID-Profile: Lucija Tudor, Matea Nikolac Perkovic, Gordana Nedic Erjavec, Ninoslav Mimica, Dubravka Svob Strac
Förderung
- Croatian Science Foundation
Zitieren
APA
Vuic, B., Milos, T., Tudor, L., Nikolac Perkovic, M., Konjevod, M., Nedic Erjavec, G., Farkas, V., Uzun, S., Mimica, N., & Svob Strac, D. (2023). Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms. Genes, 14(11), 2048. https://doi.org/10.3390/genes14112048
Vancouver
Vuic B, Milos T, Tudor L, Nikolac Perkovic M, Konjevod M, Nedic Erjavec G, et al. Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms. Genes. 2023;14(11):2048. doi:10.3390/genes14112048
BibTeX
@article{Vuic2023,
author = {Vuic, Barbara and Milos, Tina and Tudor, Lucija and Nikolac Perkovic, Matea and Konjevod, Marcela and Nedic Erjavec, Gordana and Farkas, Vladimir and Uzun, Suzana and Mimica, Ninoslav and Svob Strac, Dubravka},
title = {Pharmacogenomics of Dementia: Personalizing the Treatment of Cognitive and Neuropsychiatric Symptoms},
journal = {Genes},
year = {2023},
volume = {14},
number = {11},
pages = {2048},
doi = {10.3390/genes14112048}
}
EUVIMED